Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate ...
The global charge card market revenue was around US$ 2.44 billion in 2023 and is estimated to reach US$ 15.07 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.3% during the ...